Abstract
Neoantigens have emerged as promising targets for personalized cancer immunotherapy. However, accurate identification of immunogenic neoantigens remains a challenge due to limitations in existing predictive models. Here, we present CNNeo, a novel deep learning-based neoantigen prediction model, and CNNeoPP, an integrated computational pipeline for neoantigen discovery. CNNeo employs natural language processing-based sequence encoding and multi-modal feature integration, demonstrating superior predictive performance compared to existing tools. CNNeoPP was rigorously validated using independent datasets, including the TESLA dataset, and experimental validation via ELISpot T-cell assays. Additionally, we conducted a proof-of-concept study utilizing plasma cell-free DNA to explore the feasibility of non-invasive neoantigen prediction. We found that increased sequencing depth enhances neoantigen detectability, further amplified by by the prioritization strategy of CNNeoPP. CNNeoDB, a publicly accessible database was developed compiling neoantigen data from multiple sources. This study establishes robust tools for neoantigen prediction, with implications for optimizing cancer immunotherapy and liquid biopsy-based tumor monitoring.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was funded by the National Natural Science Foundation of China (Grant Nos. 81672627, 82071863) and the Global Learning & Academic Research Institution for Master's/PhD Students and Postdocs (LAMP) Program of the National Research Foundation of Korea (NRF), funded by the Ministry of Education (Grant No. RS-2024-00443714). The authors and their institutions did not receive any payment or services from a third party for any aspect of the submitted work, including study design, data analysis, manuscript preparation, or statistical support.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Ethics Committee of Northwest University gave ethical approval for this work. The study was approved under protocol number 24093085.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.
Subject Area
Reviews and Context
0
Comment
0
TRIP Peer Reviews
0
Community Reviews
0
Automated Services
0
Blogs/Media
Author Videos